Celgene's Focus On Execution Pays Off, But Follow-Through Is Key
Executive Summary
Third quarter sales grew 18.5% to $3.89bn, beating consensus with Otezla's contribution of 40.3% growth. After several disappointments, Celgene appears to be back on track with efforts to boost revenue before Revlimid generics hit in 2022.
You may also be interested in...
With Celgene Acquisition Closed, Bristol Faces Major Milestones
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Bristol's surprising purchase diversifies its portfolio beyond Opdivo, while stopping Celgene's ongoing stock price declines after several setbacks. While Bristol execs downplayed the mid-term risk of generics for Celgene's blockbuster Revlimid, they highlighted near- and long-term growth drivers.
Celgene’s Positive Phase III Data For Otezla In Scalp Psoriasis Could Yield Broader Label
Celgene estimates 80% of moderate-to-severe plaque psoriasis patients experience the disease in their scalps, meaning positive data in this indication could broaden the market opportunity for Otezla substantially. Novartis’ Cosentyx got scalp psoriasis added to its US label in February.